Irbesartan vs Losartan

For hypertension, irbesartan is considered more potent per milligram than losartan ^[2]. Irbesartan 150-300 mg provides greater blood pressure reduction than losartan 50-100 mg in head-to-head comparisons ^[3]. Irbesartan also has a longer duration of action, maintaining blood pressure control more consistently over 24 hours ^[2].

For diabetic nephropathy, both have landmark evidence. The IDNT trial demonstrated irbesartan reduced the composite endpoint of doubling of serum creatinine, ESRD, or death by 20% in type 2 diabetic nephropathy ^[2]. The RENAAL trial showed losartan reduced the same composite by 16% ^[1]. Both are FDA-approved for diabetic nephropathy.

For heart failure, neither has the outcomes data of candesartan or valsartan. Losartan's uricosuric effect provides a unique advantage in patients with concurrent hyperuricemia or gout — uric acid levels decrease by approximately 20-25% ^[1][3].

Both medications are well-tolerated with similar side effect profiles typical of ARBs: dizziness, headache, hyperkalemia (especially with renal impairment), and rare angioedema ^[1][2]. ARBs are known for their placebo-like tolerability and low discontinuation rates.

Both are contraindicated in pregnancy (teratogenic effects) and should not be combined with ACE inhibitors or aliskiren due to dual RAAS blockade risks ^[1][2].

The main safety distinction relates to losartan's unique drug interactions — it is partially metabolized by CYP2C9 and CYP3A4, and its active metabolite (EXP3174) actually provides most of the antihypertensive effect ^[1]. Irbesartan is metabolized primarily by CYP2C9 ^[2]. In CYP2C9 poor metabolizers, losartan may be less effective.

Both are available as affordable generics. Losartan costs $5-$15 per month ^[4]. Irbesartan costs $8-$20 per month ^[4]. Both are widely covered by insurance. Losartan is available in combination with hydrochlorothiazide (Hyzaar); irbesartan with hydrochlorothiazide (Avalide).

Both are taken once daily as oral tablets ^[1][2]. Losartan is available in 25, 50, and 100 mg tablets; irbesartan in 75, 150, and 300 mg tablets. Both can be taken with or without food. Convenience is equivalent between these medications.

Losartan may be preferred for patients with concurrent hyperuricemia or gout (unique uricosuric effect), when cost is a priority, and as a well-established first-choice ARB ^[1][3].

Irbesartan may be preferred when more potent blood pressure reduction is needed, for patients who do not achieve target BP on losartan, and based on the IDNT trial evidence for diabetic nephropathy ^[2].

Both are excellent ARBs with strong evidence bases. The choice often depends on blood pressure response and whether the uric acid-lowering benefit of losartan is clinically relevant ^[1][2][3].

This information is for educational purposes only. Consult your healthcare provider for ARB selection.